Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells

Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is a leading asexual blood-stage vaccine candidate for malaria. In preparation for clinical trials, a full-length PfRH5 protein vaccine called “RH5.1” was produced as a soluble product under cGMP using the ExpreS(2) platform (based...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:NPJ Vaccines
Päätekijät: Jin, Jing, Tarrant, Richard D., Bolam, Emma J., Angell-Manning, Philip, Soegaard, Max, Pattinson, David J., Dulal, Pawan, Silk, Sarah E., Marshall, Jennifer M., Dabbs, Rebecca A., Nugent, Fay L., Barrett, Jordan R., Hjerrild, Kathryn A., Poulsen, Lars, Jørgensen, Thomas, Brenner, Tanja, Baleanu, Ioana N., Parracho, Helena M., Tahiri-Alaoui, Abdessamad, Whale, Gary, Moyle, Sarah, Payne, Ruth O., Minassian, Angela M., Higgins, Matthew K., Detmers, Frank J., Lawrie, Alison M., Douglas, Alexander D., Smith, Robert, de Jongh, Willem A., Berrie, Eleanor, Ashfield, Rebecca, Draper, Simon J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6098134/
https://ncbi.nlm.nih.gov/pubmed/30131879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41541-018-0071-7
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia